In the REVERCE phase II trial studying early exposure to regorafenib vs. anti-EGFR in patients with CRC, Tsuji et al. identified mutations in several genes including RAS, BRAF, EGFR, HER2, and MET using ctDNA samples of patients with metastatic CRC (Clinical trial: UMIN000011294) (9). This evidence concerns the gene BRAF and colorectal carcinoma.